Diabetic macular edema (DME) is the most common reason for visual impairment in diabetic eye diseases.DME is easy to relapse and the treatment outcome is beyond satisfied.Anti-vascular endothelial growth factor (anti-VEGF) therapy has been proposed to be a first-line or key treatment regimen in the management guideline for DME.However, in clinical practice, there still are many ambiguous and controversial views in the choice and implement of different managing paradigms, including the therapeutical goal, the assessment of treatment effectiveness, the explanation of the guidelines, the regimen of anti-VEGF therapy, the value evaluation of laser photocoagulation, the use of steroids and the management of recurrent DME.Recently, the researches of treating drugs for DME are developing and making a great progress, so eye doctors should track the research results, improve the therapeutical regimen, fully understand the advantages and disadvantages of different treating methods and standardize the treatment process in order to release the best treatment effects on DME.
Authors: Dai Hong, Lu Yingyi
Cite as Chin J Exp Ophthalmol, 2016,34(12): 1061-1064.
Diabetes mellitus/complications; Macular edema/therapeutical effects; Guideline; Vascular endothelial growth factor; Laser/therapy use; Management regimen
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
(Read 33 times, 1 visits today)